Exelixis (EXEL)
(Delayed Data from NSDQ)
$37.26 USD
+1.04 (2.87%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $37.26 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Exelixis, Inc. has a PEG ratio of 0.73 compared to the Medical - Biomedical and Genetics industry's PEG ratio of 1.85.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
EXEL 37.26 +1.04(2.87%)
Will EXEL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for EXEL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EXEL
Bristol Myers Beats on Q2 Earnings and Sales, Raises '25 Sales View
Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes"
EXEL: What are Zacks experts saying now?
Zacks Private Portfolio Services
2 Highly Ranked Stocks to Consider After Q2 Earnings: CLS, EXEL
All You Need to Know About Exelixis (EXEL) Rating Upgrade to Strong Buy
EXEL Q2 Earnings Top, Sales Miss on Lower Collaboration Revenues
Other News for EXEL
Exelixis: Zanzalintinib Sees Mixed Progress, Cabozantinib Grinds Upwards
Franklin Biotechnology Discovery Fund Q2 2025 Commentary
Exelixis (EXEL) Neutral Rating Maintained by UBS, Price Target Lowered | EXEL Stock News
Exelixis (EXEL) Target Price Reduced by UBS to $38
Exelixis price target lowered by $5 at UBS